Table 3 Comparison in general parameters between groups A and B
Parameters | Group A (n = 22) | Group B (n = 45) | statistical value | P |
|---|---|---|---|---|
General information | ||||
 Male (cases) | 10 | 23 | 0.189a | 0.664 |
 Female (cases) | 12 | 22 | – | – |
 Age (years) | 63.36 ± 12.42 | 65.33 ± 12.31 | 0.613b | 0.542 |
Severity classification of COVID-19 | Â | Â | 481.5c | 0.415 |
 Mild (cases) | 7 | 19 | – | – |
 Severe (cases) | 14 | 25 | – | – |
 Critical (cases) | 1 | 1 | – | – |
Comorbidities | ||||
 Diabetes (cases) | 5 | 6 | 0.950a | 0.330 |
 Coronary heart disease (cases) | 3 | 7 | 0.043d | 0.836 |
 Cirrhosis (cases) | 0 | 1 | * | 1.000 |
 Biliary infection (cases) | 0 | 1 | * | 1.000 |
 Hypothyroidism (cases) | 0 | 1 | * | 1.000 |
 Alzheimer’s disease (cases) | 0 | 1 | * | 1.000 |
 Nasopharyngeal carcinoma (cases) | 0 | 1 | * | 1.000 |
Drugs administered to treat COVID-19 | ||||
 Lianhua Qingwen capsule | 16 | 30 | 0.252d |  |
 Moxifloxacin | 12 | 22 | 0.189d |  |
 Arbidol | 16 | 31 | 0.104d |  |
 Traditional Chinese Medicine | 21 | 41 | * |  |